help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McIntosh, C. H. S.
Right arrow Articles by Pederson, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McIntosh, C. H. S.
Right arrow Articles by Pederson, R. A.
Endocrinology Vol. 140, No. 1 398-404
Copyright © 1999 by The Endocrine Society

ARTICLES

Glucose-Dependent Insulinotropic Polypeptide Stimulation of Lipolysis in Differentiated 3T3-L1 Cells: Wortmannin-Sensitive Inhibition by Insulin1

Christopher H. S. McIntosh, Irene Bremsak, Francis C. Lynn, Ruth Gill, Simon A. Hinke, Richard Gelling, Cuilan Nian, Gary McKnight, Stephen Jaspers and Raymond A. Pederson

Department of Physiology (C.H.S.M., I.B., F.C.L., R.G., S.A.H., R.G., C.N., R.A.P.), University of British Columbia, Vancouver, British Columbia, V6T1Z3, Canada; and Zymogenetics, Inc. (G.M., S.J.), Seattle, Washington

Address all correspondence and requests for reprints to: Christopher McIntosh, Ph.D., Department of Physiology, Faculty of Medicine, University of British Columbia, 2146 Health Sciences Mall, Vancouver, British Columbia, Canada, V6T 1Z3. E-mail: mcintoch{at}unixg.ubc.ca


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Materials and Methods
 Results
 Discussion
 References
 
GIP is an important insulinotropic hormone (incretin) that has also been implicated in fat metabolism. There is controversy regarding the actions of GIP on adipocytes. In the current study, the existence of GIP receptors and effects of GIP on lipolysis were studied in differentiated 3T3-L1 cells. GIP receptor messenger RNA was detected by RT-PCR and RNase protection assay. Receptors were detected in binding studies (IC50 26.7 ± 0.7 nM). GIP stimulated glycerol release with an EC50 of 3.28 ± 0.63 nM. GIP (10-9–10-7 M) + IBMX increased cAMP production by 1180–2246%. The adenylyl cyclase inhibitor MDL 12330A (10-4 M) inhibited GIP-induced glycerol production by >90%, and reduced cAMP responses to basal. Preincubation of 3T3-L1 cells with insulin inhibited glycerol responses to GIP, and the inhibitory effect of insulin was blocked by the phosphatidylinositol 3'-kinase inhibitor, wortmannin. It is concluded that GIP stimulates glycerol release in 3T3-L1 cells primarily via stimulation of cAMP production, and that insulin antagonizes GIP-induced lipolysis in a wortmannin-sensitive fashion. It is suggested that effects of GIP on fat metabolism in vivo may depend upon the circulating insulin level, and that meal-released GIP may elevate circulating fatty acids, thus optimizing pancreatic ß-cell responsiveness to stimulation by glucose and GIP.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Materials and Methods
 Results
 Discussion
 References
 
GLUCOSE-DEPENDENT insulinotropic polypeptide (gastric inhibitory polypeptide; GIP) is released from the small intestine in response to a meal and stimulates insulin secretion in the presence of elevated circulating glucose (1, 2). This incretin action is shared by peptide products of the proglucagon gene, glucagon-like peptide-1 (GLP-1(7–36amide)) and GLP-1(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37) (3), and there is currently considerable interest in the potential of using incretin analogs for the treatment of noninsulin-dependent diabetes mellitus (NIDDM) (4). In addition to its effect on insulin secretion, GIP has also been implicated in the regulation of fat metabolism, an action that could also be of paramount importance in the normal regulation of insulin secretion (5).

Ingestion of triglycerides increases circulating GIP by a pathway that involves both metabolism (6, 7) and absorption of fatty acids (8, 9). Several lines of evidence support a role for GIP in the subsequent disposal of circulating triglycerides (10). Administration of GIP promoted chylomicron-associated triglyceride clearance from blood in dogs (11), and reduced peak plasma triglyceride levels during an intraduodenal fat infusion in rats (12). GIP has also been shown to stimulate lipoprotein lipase activity in cultured preadipocytes (13), an effect that would result in increased cellular uptake of triglycerides. There is less known regarding the direct effects of GIP on adipocyte lipid metabolism, but it has been reported to enhance incorporation of both fatty acids (10) and glucose (14) into lipids, and to inhibit glucagon-stimulated lipolysis and cAMP production (15, 16). These studies have been interpreted as being consistent with an overall anabolic effect of GIP in adipose tissue. However, in the pancreatic islet, GIP exerts its major effects via stimulation of adenylyl cyclase (17, 18). Because hormonal stimulation of release of glycerol and fatty acids from adipocytes is generally associated with increased levels of cAMP and stimulation of hormone-sensitive lipase activity (19), it would be anticipated that GIP would exhibit lipolytic, rather than lipogenic, effects.

In the current study, the presence of GIP receptors and the effect of GIP on lipolysis were studied in differentiated 3T3-L1 cells (adipocytes), a cell line which has been shown to exhibit many of the characteristics of normal adipocytes, including responsiveness to insulin and lipolytic hormones (20). GIP receptors were detected in these cells, and GIP acted as a lipolytic hormone primarily via stimulation of cAMP production. In addition, insulin was found to be capable of antagonizing GIP-induced lipolysis in a wortmannin-sensitive fashion. It is suggested that GIP-induced elevations in circulating FFA are involved in the optimization of pancreatic ß-cell responsiveness to the synergistic stimulatory actions of glucose and GIP. The response of the adipocyte to GIP may depend upon the prevailing circulating insulin level.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Materials and Methods
Results
 Discussion
 References
 
Culture of 3T3-L1 cells
3T3-L1 cells (American Type Culture Collection; ATCC) were cultured in DMEM containing high glucose and supplemented with 5% newborn calf serum plus penicillin/streptomycin (standard medium) in 12 or 24 well Corning or Falcon culture plates. Cells were induced to differentiate into the adipocyte phenotype by a modification of the method described by Rentsch and Chiesi (21). Two days after cells were confluent, medium was supplemented with dexamethasone (0.6 µM), 3-isobutyl-1-methylxanthine (IBMX; 0.1 mM) and insulin (16 µM) for 72 h, after which cells were cultured in DMEM high glucose medium + 10% FCS. Differentiation was complete in 7 days. Before use in lipolysis studies, cells were washed twice with medium consisting of (mM) NaCl (137.0), KCl (5.4), Na2HPO4 (0.34), KH2PO4 (0.44), NaHCO3 (4.2), HEPES (10.0), CaCl2 (1.26), MgSO4 (0.81), glucose (11.0), and ascorbate (0.57), pH 7.4, and incubated for 30 min in this medium. In standard protocols, cells were incubated for 4 h at 37 C in the above medium containing 2% fatty acid free BSA, gassed with 5% CO2, in the absence or presence of the ligands described in the text. The medium was removed and frozen at -20 C. Fully differentiated cells (>85% adipose cells) from passages 3–9 were used in all experiments.

GIP receptor: RT-PCR analysis
Total RNA was isolated from 3T3-L1 cells (passage 7) or rat epididymal fat using a modification of the method of Chomczynski and Sacchi (22) (Trizol; Gibco BRL, Life Technologies, Burlington, Ontario, Canada). Total RNA (2 µg) was reverse transcribed in a 20 µl reaction mixture containing 0.5 mM dNTPs, 30 pmol 3' gene specific primer, 200 U Superscript II RNase H- Reverse Transcriptase (Gibco BRL), 10 U RNAase inhibitor (RNA Guard; Pharmacia Biotech, Québec, Canada), 1 mM dithiothreitol, 50 mM Tris-HCl, pH 8.3, 75 mM KCl, and 3 mM MgCl2. Following RT, 2 µl of the RT mix was amplified in a 50 µl PCR reaction containing 67 mM Tris-HCl, 3.0 mM MgSO4, 166 mM (NH4)2SO4, 10 mM ß-mercaptoethanol, pH 8.3, with 200 µM dNTPs, 10 pmol of each primer (FCL5': 5'-ACCTGTACGAGAACACGCAGTGC-3' and FCL3': 5'-GTTCTGGAGTAGAGGTCCGTGTA-3'), and 1 U of Taq DNA Polymerase. The PCR reaction profile included a 5-min initial denaturation step at 94 C followed by 40 cycles of 94 C (45 sec), 59 C (1 min), 72 C (1 min), and a final extension step for 5 min at 72 C.

GIP receptor: ribonuclease protection assay
All reagents used in the ribonuclease protection assay were from Ambion, Inc. (Austin, TX). An antisense probe of approximately 300 nucleotides, complementary to the C-terminal tail of the GIP receptor DNA, was transcribed using the Megascript SP6 kit. A sense control probe consisting of a 200 nucleotide fragment of the antisense probe was transcribed in the same manner. A probe complementary to 80 nucleotides of 18S ribosomal RNA was also transcribed using pTRI RNA 18S antisense Control Template. Probes were labeled with biotin using the Brightstar Psoralen-Biotin Nonisotopic labeling Kit. Total RNA (5 µg) from either 3T3-L1 cells or rat adipose tissue was coprecipitated with 190 ng of antisense probe, 50 pg of sense probe and 420 ng of 18S ribosomal probe, resuspended in hybridization buffer, and hybridized at 44 C for 18 h. Single-stranded RNA was digested with RNase A and RNase T1 at 37 C for 30 min using RPA II kit reagents. Double-stranded RNA was precipitated, subjected to electrophoresis on a 5% acrylamide/8M urea gel, and transferred to a positively charged nylon membrane. Biotinylated RNA was detected using a streptavidin-alkaline phosphatase conjugate that binds CDP-Star to give a chemiluminescent signal. The membrane was exposed to film for 2.5 min.

Iodination of GIP and binding analysis
Synthetic porcine GIP (5 µg) was iodinated by the chloramine-T method, and the 125I-GIP further purified by reverse phase HPLC to a specific activity of 250–350 µCi/µg (17). Aliquots of tracer were lyophilized and stored at -20 C until use. Binding analysis was performed as described previously (17) with minor modifications. Briefly, 3T3-L1 cells (1.9 x 105/well) were washed twice in binding buffer (DMEM/F12, 20 mM HEPES and 0.1% BSA, pH 7.4) at 4 C, and incubated for 4 h at 4 C with 125I-GIP (50,000 cpm) + 100 KIU aprotinin (Trasylol), in the presence or absence of unlabeled synthetic human GIP (final volume 200 µl). Binding to CHO-K1 cells (2 x 105/well), transfected with the wild-type GIP receptor (wtGIP-R1) and grown as described previously (17), was analyzed in parallel. Following incubation, cells were washed twice in ice cold buffer, solubilized with 0.1M NaOH (1.0 ml), and transferred to test tubes for counting of cell associated radioactivity. Nonspecific binding was defined as that measured in the presence of an excess of shGIP (1 µM) and specific binding was expressed as a percentage of binding in the absence of competitor (%B/Bo).

Measurement of glycerol release
Following incubation of 3T3-L1 cells, for the time periods indicated in figure legends, proteins in the incubation medium were precipitated with 1/10 vol. of 7% (wt/vol) ZnSO4, incubated on ice for 10 min, and 1/5 vol. 0.1 M NaOH added at room temp. The mixture was centrifuged and the supernatant assayed for glycerol with an enzymatic assay based on the method of Wieland (23) using reagents from Boehringer Mannheim (Mannheim, Germany). Data are expressed as means ± SEM of glycerol released per well (nmol/well), or nmol change from basal when preincubation of cells with a specific agent resulted in an altered basal secretion. The number of experiments is presented in brackets.

Measurement of cAMP production
In selected experiments, indicated in the Results section, glycerol release, and cAMP production were assayed in parallel. Following incubation, medium was removed for glycerol assay, and cells were extracted with 70% ethanol. The extract was dried by vacuum centrifugation, and cAMP levels measured by RIA (Biomedical Technologies, Stoughton, MA) as previously described (17). Data are expressed as means ± SEM of cAMP production in pmol/well. Number of experiments is presented in brackets.

Data analysis
Binding, glycerol release and cAMP data were analyzed using the nonlinear regression analysis program Prism (GraphPad, San Diego, CA). Statistical analysis was performed using Student’s t test. Maximal cAMP and mean EC50 values were compared using one-way ANOVA, followed by Dunnett’s multiple comparison test. P < 0.05 was considered significant.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Materials and Methods
Results
 Discussion
 References
 
Porcine GIP1–42 was from Bachem California, Inc. (Torrance, CA) and Human GIP1–42 was synthesized by Hukabel, Montréal, Canada. MDL 12330A, IBMX and wortmannin were obtained from Research Biochemicals International. Tissue culture reagents were from Gibco BRL, Life Technologies. All other chemicals, of reagent or molecular biology grade were from Fisher Scientific International, Inc. (Vancouver, Canada).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Materials and Methods
 Results
Discussion
 References
 
The 3T3-L1 cell GIP receptor: expression and binding
RT-PCR was performed on RNA extracted from differentiated 3T3-L1 cells and rat epididymal fat. Primers were designed to allow amplification of the carboxy terminal region of the GIP receptor. A PCR product was detected after amplification of complementary DNA (cDNA) from both extracts with the predicted size (526 bp) (Fig. 1AGo). With the RNase protection assay a band was detected for extracts from both 3T3-L1 cells and adipose tissue corresponding to a transcript of the appropriate size for the C-terminal region of the GIP receptor (Fig. 1BGo)



View larger version (77K):
[in this window]
[in a new window]
  		Figure 1. Demonstration of the presence of GIP receptor messenger RNA in extracts of 3T3-L1 cells using RT-PCR (A) and ribonuclease protection assay (B). RT-PCR and the RNAase assay were performed as described under Materials and Methods. RT-PCR (A): 1 = Molecular weight standards (1 kb ladder); 2 = Amplification of 3T3-L1 cell cDNA; 3 = Amplification of adipocyte cDNA. RNAase Assay: 1 = Molecular weight standards; 2 = 3T3-L1 cell RNA; 3 = adipocyte RNA. *, GIP receptor. Bands at 200 and 80 nucleotides = Sense and RNA 18S RNA.

 
Binding of 125I-GIP to 3T3-L1 cells was significantly less than to wtGIP-R1 transfected CHO-K1 cells, or to ß cell (ßTC-3) tumor cells (unpublished observations). The IC50 value of 26.7 ± 0.7 nM (n = 5) was approximately 10.5-fold greater than that for wtGIP-R1 (2.55 ± 0.44 nM; n = 4) (Fig. 2Go).



View larger version (15K):
[in this window]
[in a new window]
  		Figure 2. Displacement of 125I-GIP binding by GIP in 3T3-L1 cells and CHO-K1 cells expressing GIP receptors. Competitive binding studies were performed as described in Materials and Methods, and binding expressed as B/Bo, where B and Bo = binding in the presence and absence of unlabeled ligand, respectively (wtGIP-R1 cells n = 4, 3T3-L1 cells n = 5).

 
Effect of GIP on lipolysis and cAMP production
Under the standard incubation conditions used (4 h, 37 C), GIP-stimulated glycerol release from 3T3-L1 adipocytes in a concentration-dependent manner over the range 10-10–10-6 M (Fig. 3AGo). Maximal stimulation was approximately 70% of that obtained with isoproterenol (Fig. 3BGo). Over the same concentration range neither glucagon nor GLP-1 (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)amide, structurally related insulinotropic peptides, had any significant effect on glycerol release.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 3. Glycerol release from 3T3-L1 adipocytes in response to GIP (A) and isoproterenol (B). Cells were incubated under standard conditions for 4 h, as described in Materials and Methods, the medium removed and glycerol content measured. n = 11 for GIP and 6 for isoproterenol.

 
The EC50 value for GIP stimulation, averaged over several cell passages, was 3.28 ± 0.63 x 10-9 M (n = 11), whereas with isoproterenol it was two orders of magnitude lower: 4.68 ± 0.94 x 10-11 M (n = 6). Addition of low concentrations of IBMX (10-6 M) to the medium potentiated glycerol release (~38%) under basal conditions, and in response to 10 nM GIP (~24%), suggesting that the effect of GIP on lipolysis was mediated via stimulation of adenylyl cyclase. However, when cells were incubated for time periods in excess of 30 min with concentrations of IBMX sufficient to maximally block phosphodiesterase activity (1–2 mM), subsequent responses to GIP were reduced or abolished. Preincubation with forskolin (50 µM) resulted in similar reductions in responsiveness, indicating that it was probably due to cAMP-mediated desensitization. Therefore, when examining the effect of IBMX on cAMP responses only 30 min exposures were used. Under these conditions, basal cAMP levels, in the absence and presence of IBMX, were 2.75 ± 0.06 and 25.18 ± 0.86 pmol/well respectively. GIP resulted in concentration-dependent increases in cAMP (n = 6): at concentrations of 10-9, 10-8, and 10-7 M GIP cAMP levels were 3.51 ± 0.18, 7.63 ± 0.27 and 18.51 ± 2.04 pmol/well in the absence of IBMX, and 44.94 ± 2.19, 179.03 ± 11 and 376 ± 35.2 pmol/well in its presence.

Effect of inhibition of adenylyl cyclase on GIP-stimulated glycerol release
To establish that GIP-stimulated release of glycerol was associated with increased cAMP production, a study was made on the effect of the adenylyl cyclase inhibitor MDL 12330A on both parameters. A strong link between GIP-induced cAMP production and glycerol release was obtained in a study in which both parameters were measured over time in the presence and absence of 10-4 M MDL 12330A (Fig. 4Go). Glycerol secretion continued throughout the 120 min. experimental period (Fig. 4AGo). cAMP accumulation reached a peak within 15 min (Fig. 4BGo). In the presence of 10-9 M GIP cAMP levels returned to basal by 60 min whereas, with GIP at higher concentrations, cAMP remained elevated, although at levels less than those at 15 min. MDL 12330A almost completely abolished cAMP responses (Fig. 4DGo), apart from those in the presence of 10-7 M GIP. Glycerol production was significantly reduced by MDL 12330A at all time periods (Fig. 4CGo; P < 0.05).



View larger version (43K):
[in this window]
[in a new window]
  		Figure 4. Time-responses of glycerol and cAMP to GIP in 3T3-L1 adipocytes in the absence and presence of MDL 12330A. Cells were preincubated in the absence (A and B) or presence (C and D) of MDL 12330A (10-4 M) for 30 min, followed by incubation for the indicated time periods with the addition of GIP (10-10–10-6 M) (n = 6). At the indicated times medium was removed for glycerol measurement (A and C), and the cells extracted for cAMP assay (B and D). Both glycerol and cAMP responses in the presence of MDL 12330A were significantly reduced at all concentrations of GIP over the complete time period (P < 0.05).

 
Effect of insulin on GIP-stimulated glycerol release
Preincubation of cells for 30 min with insulin reduced basal glycerol release, and inhibited responses to both GIP (10-8 M) and isoproterenol (10-10 M) in a concentration-dependent manner (Fig. 5AGo). Significant inhibition (P < 0.05) was obtained at an insulin concentration of 10-11 M (n = 6–7; P < 0.05), and 50% inhibition of responses occurred at in-sulin concentrations of 1.07 x 10-10 M with GIP and at 0.75 x 10-10 M with isoproterenol. Maximum inhibition, obtained with an insulin concentration of 10-8 M, was 71.6 ± 6.1% with GIP and 85.2 ± 5.5% with isoproterenol. When cells were preincubated with a low concentration of insulin (10-10 M) and GIP responses subsequently measured in its presence, responses were reduced throughout the GIP concentration range (Fig. 5BGo).



View larger version (17K):
[in this window]
[in a new window]
  		Figure 5. Inhibition of glycerol responses to GIP and isoproterenol in 3T3-L1 adipocytes by varying concentrations of insulin (A) and concentration-response to GIP in the presence and absence of insulin (B). For (A) glycerol was measured in the medium from cells preincubated with insulin for 30 min, followed by a 4 h incubation in the presence of GIP (10-8 M) (n = 6). For (B) cells were preincubated with insulin (10-10 M), followed by the addition of GIP (10-10–10-6 M) (n = 6–8). Data are expressed as % inhibition of responses in the absence of insulin. In (A) responses were significantly inhibited at concentrations >10-11 M insulin, and in (B) GIP responses were inhibited throughout the concentration range (P < 0.05).

 
Effect of wortmannin on insulin-induced inhibition of responses to GIP
To determine whether the inhibitory effect of insulin on GIP-induced glycerol release was associated with the stimulation of phosphatidylinositol (PI) 3'-kinase, the effect of the selective inhibitor wortmannin on responses to GIP was tested. Incubation of 3T3-L1 adipocytes with wortmannin at concentrations of 10-9–10-7 M had no effect on basal glycerol release: rates were 47.8 ± 0.8 nmol per well in the absence and 48.8 ± 2.3 nmol per well (n = 6) in the presence of 10-7 M wortmannin. GIP (10-6 M)-stimulated glycerol release was likewise unaffected: 64 ± 3.6 nmol per well in the absence and 66.5 ± 3.5 nmol per well in the presence of wortmannin. In agreement with the previous experiments (Fig. 5Go), insulin (10-8 M) completely inhibited glycerol release in response to 10-9 M GIP, and inhibited by >60% responses to 10-8 and 10-7 M GIP (Fig. 6Go). When cells were preincubated with wortmannin (10-7 M) for 30 min and subsequently incubated in the presence of insulin plus GIP, responses to 10-8 and 10-7 M GIP were not significantly different from those to GIP alone (Fig. 6Go), indicating almost complete abolition of insulin’s inhibitory action.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 6. Effect of wortmannin on insulin inhibition of GIP-stimulated glycerol release. Cells were preincubated with insulin or insulin + wortmannin for 30 min, followed by a 4 h incubation with the addition of GIP (10-8 M) (n = 6). Insulin resulted in a reduction in basal glycerol release. Therefore, to allow comparison, data were calculated as the change from basal levels in the absence or presence of wortmannin. Following wortmannin treatment responses to GIP were not significantly different from responses to GIP in the absence of insulin.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Materials and Methods
 Results
 Discussion
References
 
There is convincing evidence in the literature that GIP is involved in the clearance of postprandial circulating triglycerides (11, 12), and such a function is consistent with fat being the most powerful stimulus for GIP secretion (1, 2). In contrast, the literature regarding direct effects of GIP on fat cell triglyceride metabolism is less definitive. Dupre and co-workers (16) reported that GIP was nonlipolytic on adipocytes from rat epididymal fat pad, but that it inhibited both glucagon-stimulated lipolysis and cAMP production. In contrast, Ebert and Creutzfeldt (15), using a similar adipocyte preparation, found that GIP stimulated cAMP production and induced small increases in glycerol release. Both groups reported that GIP displaced 125I-glucagon binding from adipocytes, implying that GIP interacted with the glucagon receptor (15, 16). An important implication from these studies was that the predominant effect of GIP on lipolysis was mediated via the glucagon receptor. It had been observed by us earlier (reviewed in Refs. 1, 24) that pancreatic islets isolated by collagenase digestion were only weakly responsive to GIP, presumably due to receptor damage by the enzymatic digestion. Because rat adipocytes are isolated using a similar procedure, reduced receptor content may explain the previous inability to observe specific GIP effects on lipolysis. An additional factor may have been the use of high concentrations of phosphodiesterase inhibitors because, as described in this study, such treatment results in greatly reduced responsiveness, possibly due to receptor desensitization.

The 3T3-L1 cell line has been used extensively for studying the mode of action of lipolytic and lipogenic hormones. Differentiation of 3T3-L1 preadipocytes is accompanied by increases in proteins characteristic of mature adipocytes including catecholamine-stimulated adenylyl cyclase (25), hormone-sensitive lipase (26), and cAMP phosphodiesterase (27). The differentiated cells are also responsive to many lipolytic hormones (20), and these cells were therefore considered appropriate for examining a possible lipolytic action for GIP.

The 3T3-L1 adipocytes express a GIP receptor with similar characteristics to that from the rat pancreatic islet (17, 18) although it appears that, under the conditions of culture used, the receptor population is mainly in a lower affinity state. It is clear that GIP is a fairly potent lipolytic hormone in 3T3-L1 adipocytes, and that it acts primarily via stimulation of cAMP production. The 3T3-L1 adipocytes used in the current study were found to be unresponsive to glucagon, in agreement with earlier studies (20, 28), and GIP effects could not, therefore, have been mediated via the glucagon receptor. Recently, GLP-1 (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) was described as having insulin-like effects in 3T3-L1 cells, reducing cAMP production (29), and increasing glucose uptake and expression of the glucose transporters GLUT1 and GLUT4 (30), whereas GIP was without effect. In contrast, we did not observe any effect of GLP-1(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) on either cAMP or glycerol production (data not shown). Interestingly, Montroze-Rafizadeh et al. (29) were unable to demonstrate the presence in 3T3-L1 cells of the G protein-coupled GLP-1 receptor identified in pancreatic islets, and proposed the existence of a second receptor type. The differences in peptide-induced cAMP responses between the two cultured cell preparations could be due to the conditions of culture and differentiation, since in our studies the degree of responsiveness to GIP was found to be passage-dependent.

A strong link between GIP stimulation of adenylyl cyclase and lipolysis was demonstrated by the use of MDL 12330A (alternatively termed RMI 12330A), a compound that has been shown to inhibit adenylyl cyclase in a number of cell types in parallel with the inhibition of cAMP-mediated responses. This includes myocardial function (31), glucose-induced insulin biosynthesis (32), and induction of retinal N-acetyltransferase activity (33). In the time studies MDL 12330A, at a concentration of 10-4 M, reduced cAMP responses considerably, and this was paralleled by a reduction in GIP-stimulated glycerol release. The concentration required to inhibit adenylyl cyclase is similar to that previously shown to be necessary in heart cells (31). These results, in combination with those demonstrating potentiation by inhibition of phosphodiesterase, provide strong evidence in support of a causal link between cAMP and GIP-induced glycerol production.

Beck and Max (reviewed in Ref. 10) reported that GIP stimulated FA and glucose uptake into adipocytes from epididymal fat pads, and that the former involved an insulin-dependent, but cAMP-independent, pathway. Because the experiments on 3T3-L1 cells were performed in the absence of insulin, it was considered possible that the observed catabolic effects of GIP were a consequence of this absence. However, studies on the effect of insulin on GIP-stimulated glycerol release revealed that addition of insulin resulted in a concentration-dependent inhibition of both GIP- and isoproterenol-stimulated lipolysis. When cells were incubated in the presence of 10-10 M insulin, a concentration equivalent to that found circulating early postprandially (34), responses were significantly reduced over the complete GIP concentration range. Therefore, GIP is probably only capable of stimulating lipolysis during fasting, and in the period immediately following glucose absorption.

Insulin’s suppressive effect on catecholamine-induced lipolysis has been shown to involve activation of cAMP phosphodiesterase (27, 35), resulting in reduced cAMP levels, and dephosphorylation of hormone-sensitive lipase via activation of a protein phosphatase (36). Additionally, insulin-receptor interaction has been shown to result in phosphorylation of tyrosine residues in G protein-coupled receptors, including the ß2-adrenergic receptor, an effect that is believed to be directly mediated by the intrinsic tyrosine kinase activity of the insulin receptor (37, 38). Although the mouse GIP receptor has not been completely sequenced as yet, the rat receptor contains a tyrosine residue in the third intracellular loop, and a second in the C-terminal tail, which are potential phosphorylation sites (Tyr332 and Tyr454). It is difficult to predict, without evidence of definitive tyrosine kinase consensus sequences (39), but it is possible that tyrosine phosphorylation of the GIP receptor is involved in insulin’s antagonistic action.

It has been demonstrated that wortmannin, a selective inhibitor of phosphatidylinositol (PI) 3'-kinase, blocks insulin-induced inhibition of isoproterenol-stimulated lipolysis, suggesting that this enzyme is involved in insulin’s inhibitory effect on hormone-stimulated lipase (40). Wortmannin has also been reported recently to cause partial inhibition of GIP-stimulated insulin secretion from HIT cells (41) and GIP-activated MAP kinase in GIP receptor-transfected CHO cells (42). In contrast, in the present study, wortmannin was not found to have any effect on GIP-induced lipolysis, suggesting that the signal-transduction pathways activated by GIP are cell specific. However, preincubation of 3T3-L1 adipocytes with wortmannin blocked insulin-mediated inhibition of GIP-induced lypolysis, implicating PI-3-kinase. The question of specificity is a concern with wortmannin, because it has have been reported to exert various nonspecific effects. However, PI-3-kinase involvement in the antilipolytic action of insulin is well established (43, 44), and it seems likely that this enzyme is involved in insulin’s effect on GIP-stimulated lipolysis. The pathway involved, however, is unclear. It is currently accepted that following insulin binding, insulin receptor substrates (IRSs) are tyrosine phosphorylated, and interact with the p85 subunit of PI 3'-kinase via src-homology 2 (SH2) domains (45). Subsequent events are not, however, clearly delineated. The phosphatidylinositol (PI) products, PI-3-P, PI-3,4-P2 and PI-3,4,5-P3 are clearly the most important second messengers. PI-3,4,5-P3 has been shown to activate isoforms of protein kinase C (PKC) (46), and the rat GIP receptor contains the PKC consensus sequence Val-Val-Val-Arg-Arg-Ser-Glu-Lys-Gly in the second intracellular loop (243–251), suggesting one possible pathway. Alternatively, because at least one of the multiple forms of PI-3-kinase (46) acts as a dual specificity kinase, possessing both lipid and serine kinase activities (46), phosphorylation of serines in the intracellular loops or C-terminal tail could be involved in the PI 3'-kinase-mediated effect.

In summary, the current study provides strong evidence for a lipolytic effect of GIP in 3T3-L1 adipocytes, and a wortmannin-sensitive inhibition by insulin. Although the current results need to be replicated with primary adipocytes in vitro, and in vivo lipolytic responses to GIP must be established, a possible physiological for GIP may be associated with the recent demonstration that circulating fatty acids are essential for optimal glucose stimulation of insulin secretion following fasting (47). GIP could be capable of stimulating lipolysis under conditions in which insulin levels are of insufficient magnitude to inhibit its action, and this may ensure that levels of circulating FFAs are optimal for glucose- and GIP-stimulated insulin secretion. Such a proposal is open to experimental verification.


   Footnotes
 
1 This work was supported by grants from Zymogenetics Inc. (Seattle, WA), the Medical Research Council of Canada (5–90007-RAP/CHSM) and the Canadian Diabetes Association (CHSM/RAP). Back

Received July 10, 1998.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Materials and Methods
 Results
 Discussion
 References
 

  1. Brown JC, Buchan AMJ, McIntosh CHS, Pederson RA 1989 Gastric inhibitory polypeptide. In: Schultz SG, Makhlouf GM, Rauner BB (eds) Handbook of Physiology, Section 6 (The Gastrointestinal System). American Physiology Society, Bethesda, pp 403–430
  2. Pederson RA 1993 Gastric inhibitory polypeptide. In: Walsh J, Dockray G (eds) Gut Peptides. Raven Press, New York, pp 217–259
  3. Habener JF 1993 The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am 22:775–794[Medline]
  4. Gutniak MK, Holst JJ, Linde B, Efendic S 1994 Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039–1044[Abstract]
  5. McGarry JD 1998 Glucose-fatty acid interactions in health and disease. Am J Clin Nutr [ 67:500S–504S
  6. Ross SA, Shaffer EA 1981 The importance of triglyceride hydrolysis for the release of gastric inhibitory polypeptide. Gastroenterology 80:108–111[Medline]
  7. Yoshidome K, Miyata M, Izukura M, Mizutani S, Sakamoto T, Tominaga H, Matsuda H 1995 Secretion of gastric inhibitory polypeptide in patients with bile duct obstruction. Scand J Gastroenterol 30:586–589[Medline]
  8. Ebert R, Creutzfeldt W 1980 Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia 19:198–204[CrossRef][Medline]
  9. O’Dorisio TM, Cataland S, Stevenson M, Mazzaferri EL 1976 Gastric inhibitory polypeptide (GIP). Intestinal distribution and stimulation by amino acids and medium-chain triglycerides. Am J Dig Dis 21:761–765[CrossRef][Medline]
  10. Beck B 1989 Gastric inhibitory polypeptide: a gut hormone with anabolic functions. J Mol Endocrinol 2:169–174[Abstract/Free Full Text]
  11. Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Unger RH 1981 Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest 68:1106–1107
  12. Ebert R, Nauck M, Creutzfeldt W 1991 Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm Metab Res 23:517–521[Medline]
  13. Eckel RH, Fujimoto WY, Brunzell JD 1979 Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 28:1141–1142[Abstract]
  14. Hauner H, Glatting G, Kaminska D, Pfeiffer EF 1988 Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann Nutr Metab 32:282–288[Medline]
  15. Ebert R, Creutzfeldt W 1987 Metabolic effects of gastric inhibitory polypeptide. Front Horm Res 16:175–185
  16. Dupre J, Greenidge N, McDonald TJ, Ross SA, Rubinstein D 1976 Inhibition of actions of glucagon in adipocytes by gastric inhibitory polypeptide. Metabolism 25:1197–1199[Medline]
  17. Wheeler MB, Gelling RW, McIntosh CHS, Georgiou J, Brown JC, Pederson RA 1995 Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide (GIP) receptor: ligand binding and intracellular signaling properties. Endocrinology 136:4629–4639[Abstract]
  18. Gelling RW, Wheeler MB, Xue J, Gyomorey S, Nian C, Pederson RA, McIntosh CHS 1997 Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor. Endocrinology 138:2640–2642[Abstract/Free Full Text]
  19. Yeaman SJ 1990 Hormone-sensitive lipase-a multipurpose enzyme in lipid metabolism. Biochim Biophys Acta 1052:128–132[Medline]
  20. Rosen OM, Smith CJ, Hirsch A, Lai E, Rubin CS 1979 Recent studies of the 3T3–L1 adipocyte-like cell line. Recent Prog Horm Res 35:477–499
  21. Rentsch J, Chiesi M 1996 Regulation of ob gene mRNA levels in cultured adipocytes. FEBS Lett 379:55–59[CrossRef][Medline]
  22. ChomczynskiP, Sacchi N 1987 Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159[Medline]
  23. Wieland O 1974 Glycerol U.V. method. In: Burgmeyer HU (ed) Methods of Enzymatic Analysis. Academic Press, New York, vol 4:1404–1409
  24. McIntosh CHS, Wheeler MB, Gelling RW, Brown JC, Pederson RA 1996 GIP receptors and signal-transduction mechanisms. Acta Physiol Scand 157:361–365[CrossRef][Medline]
  25. Lai E, Rosen OM, Rubin CS 1981 Differentiation-dependent expression of catecholamine-stimulated adenylate cyclase. Roles of the ß-receptor and G/F protein in differentiating 3T3–L1 adipocytes. J Biol Chem 256:12866–12874[Free Full Text]
  26. Kawamura M, Jensen DF, Wancewicz EV, Joy LL, Khoo JC, Steinberg D 1981 Hormone-sensitive lipase in differentiated 3T3–L1 cells and its activation by cyclic AMP-dependent protein kinase. Proc Natl Acad Sci USA 78:732–736[Abstract/Free Full Text]
  27. Elks ML, Manganiello VC, Vaughan MJ 1983 Hormone-sensitive particulate cAMP phosphodiesterase activity in 3T3–L1 adipocytes. Regulation of responsiveness by dexamethasone. J Biol Chem 258:8582–8587[Abstract/Free Full Text]
  28. Hirsch AH, Rosen OM 1984 Lipolytic stimulation modulates the subcellular distribution of hormone-sensitive lipase in 3T3–L1 cells. J Lipid Res 25:665–677[Abstract]
  29. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams L G 1997 Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3–L1 adipocytes. J Cell Physiol 172:275–283[CrossRef][Medline]
  30. Wang Y, Kole HK, Montrose-Rafizadeh C, Perfetti R, Bernier M, Egan J M 1997 Regulation of glucose transporters and hexose uptake in 3T3–L1 adipocytes: glucagon-like peptide-1 and insulin interactions. J Mol Endocrinol 19:241–248[Abstract/Free Full Text]
  31. Grupp G, Grupp IL, Johnson CL, Matlib MA, Rouslin W, Schwartz A, Wallick ET, Wang T, Wisler P 1980 Effects of RMI 12330A, a new inhibitor of adenylate cyclase on myocardial function and subcellular activity. Br J Pharmacol 70:429–442[Medline]
  32. Simpson AM, Tuch BE 1995 Control of insulin biosynthesis in the human fetal beta cell. Pancreas 11:48–54[Medline]
  33. Gan J, Alonso-Gomez AL, Avendano G, Johnson B, Iuvone PM 1995 Melatonin biosynthesis in photoreceptor-enriched chick retinal cell cultures: role of cyclic AMP in the K+-evoked, Ca2+-dependent induction of serotonin N-acetyltransferase activity. Neurochem Int 27:147–155[CrossRef][Medline]
  34. Flakoll P, Carlson MG, Cherrington A 1996 Physiologic action of insulin. In: LeRoith D, Taylor SI, Olefsky JM (eds) Diabetes Mellitus. Lippincott-Raven, Philadelphia, pp 121–132
  35. Degerman E, Belfrag P, Manganiello VC 1997 Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272:6823–6826[Free Full Text]
  36. Strålfors P, Honnor RC 1989 Insulin-induced dephosphorylation of hormone-sensitive lipase. Correlation with lipolysis and cAMP-dependent protein kinase activity. Eur J Biochem 182:379–385[Medline]
  37. Karoor V, Baltensperger K, Paul H, Czech MP, Malbon CC 1995 Phosphorylation of tyrosyl residues 350/354 of the ß-adrenergic receptor is obligatory for counterregulatory effects of insulin. J Biol Chem 270:25305–25308[Abstract/Free Full Text]
  38. Baltensperger K, Karoor V, Paul H, Ruoho A, Czech MP, Malbon CC 1996 The ß-adrenergic receptor is a substrate for the insulin receptor tyrosine kinase. J Biol Chem 271:1061–1064[Abstract/Free Full Text]
  39. Geahlen R, Harrison ML 1990 Protein-tyrosine kinases. In: Kemp BE (ed) Peptides and Protein Phosphorylation. CRC Press, Boca Baton, FL, pp 239–253
  40. Lam K, Carpenter CL, Ruderman NB, Friel JC, Kelly KL 1994 The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by wortmannin. J Biol Chem 269:20648–20652[Abstract/Free Full Text]
  41. Straub SG, Sharp GWG 1996 Glucose-dependent insulinotropic polypeptide stimulates insulin secretion via increased cyclic AMP and [Ca2+]i and a wortmannin-sensitive signalling pathway. Biochem Biophys Res Commun 224:369–374[CrossRef][Medline]
  42. Kubota A, Yamada Y, Yasuda K, Someya Y, Ihara Y, Kagimoto S, Watanabe R, Kuroe A, Ishida H, Seino Y 1997 Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways. Biochem Biophys Res Commun 236:171–175
  43. Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M 1994 Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with the selective inhibitor wortmannin. J Biol Chem 269:3568–3573[Abstract/Free Full Text]
  44. Evans JL, Honer CM, Womelsdorf BE, Kaplan EL, Bell PA 1995 The effects of wortmannin, a potent inhibitor of phosphatidyl-inositol 3-kinase, on insulin-stimulated glucose transport, GLUT4 translocation, antilipolysis, and DNA synthesis. Cell Signal 7:365–376[CrossRef][Medline]
  45. White MF 1997 The insulin signalling system and the IRS proteins. Diabetologia 40:S2–S17
  46. Toker A, Cantley LC 1997 Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387:673–676[CrossRef][Medline]
  47. Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JD 1996 Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 97:2728–2735[Medline]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S.-J. Kim, C. Nian, and C. H. S. McIntosh
Resistin Is a Key Mediator of Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Lipoprotein Lipase (LPL) Activity in Adipocytes
J. Biol. Chem., November 23, 2007; 282(47): 34139 - 34147.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S.-J. Kim, C. Nian, and C. H. S. McIntosh
Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes: A ROLE FOR A PROTEIN KINASE B, LKB1, AND AMP-ACTIVATED PROTEIN KINASE CASCADE
J. Biol. Chem., March 23, 2007; 282(12): 8557 - 8567.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
B. D Green, P. R Flatt, and C. J Bailey
Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 159 - 165.
[Abstract] [PDF]

Home page
 EndocrinologyHome page
L. Akesson, B. Ahren, V. C. Manganiello, L. S. Holst, G. Edgren, and E. Degerman
Dual Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Isoproterenol on Lipid Metabolism and Signaling in Primary Rat Adipocytes
Endocrinology, December 1, 2003; 144(12): 5293 - 5299.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. A. Ehses, S. S. T. Lee, R. A. Pederson, and C. H. S. McIntosh
A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling. EVIDENCE FOR THE INVOLVEMENT OF PHOSPHOLIPASE A2 IN GIP-STIMULATED INSULIN SECRETION
J. Biol. Chem., June 22, 2001; 276(26): 23667 - 23673.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McIntosh, C. H. S.
Right arrow Articles by Pederson, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McIntosh, C. H. S.
Right arrow Articles by Pederson, R. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals